BrainChip (BRN) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
1 Dec, 2025Executive summary
Ended the quarter with a cash balance of $13.9M, up from $13.5M in the prior quarter.
Advanced AKD1500 neuromorphic processor from reference design to volume production, driven by strong customer engagement in defense, aerospace, medical, and consumer wearables.
Expanded global IP portfolio to 57 issued and pending patents, reinforcing competitive positioning in edge AI.
Entered strategic supply agreement with Parsons Corporation for AKD1500 integration into defense platforms.
Broadened distribution through DigiKey, making Akida-based development boards globally accessible.
Financial highlights
Net operating cash outflows of $4.9M, higher than $2.8M in the prior quarter.
Customer cash inflows of $0.3M, down from $1.4M in the previous quarter due to lower engineering revenues.
Payments to suppliers and employees totaled $5.2M, up from $4.4M, reflecting merit increases, higher contractor fees, and corporate costs.
Cash inflows from financing activities of $5.4M from a capital call, with an average subscription price of A$0.2059 per share.
Estimated 2.96 quarters of funding available based on current cash burn and available facilities.
Outlook and guidance
Volume production of AKD1500 expected to drive scalable revenue growth, supported by strategic agreements and expanded distribution.
Enhanced full-stack AI capabilities position the company as a comprehensive AI solutions provider.
Latest events from BrainChip
- Cash outflows improved as AKD1500 production scaled and new commercial partnerships expanded.BRN
Q4 2026 - AGM focused on product innovation, commercial growth, and shareholder engagement challenges.BRN
AGM 2025 - Cash outflows improved, R&D consolidated, and new collaborations drive commercialization efforts.BRN
Q2 2024 - Strategic growth, new edge AI products, and governance dominated, with robust shareholder engagement.BRN
AGM 2026 - Revenue up 72% and net loss reduced, with strong capital raises and edge AI focus for 2025.BRN
H2 2024 - Revenue up 374% to $1.89M, net loss narrows, AKD1500 enters production, capital base strengthened.BRN
H2 2025 - Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.BRN
Q4 2025 - $35M placement and $2M SPP to accelerate edge AI commercialization and product expansion.BRN
Investor Presentation - Edge AI and neuromorphic solutions drive growth across defense, healthcare, and consumer markets.BRN
Investor Presentation